Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2017 13:00 ET | Source: Radius Health Inc.

New National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures

Joint Survey from National Osteoporosis Foundation, HealthyWomen and Radius Health Sounds an Urgent Call to Action for Women to Know Their Risk, Get the Facts ‘Fractured Truth’ Education Campaign...
August 08, 2017 23:16 ET | Source: Radius Health Inc.

Radius Health Announces Pricing of $300 Million of 3.00% Convertible Senior Notes due 2024

WALTHAM, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced the pricing of $300 million aggregate principal amount of 3.00%...
August 07, 2017 16:22 ET | Source: Radius Health Inc.

Radius Health Announces Proposed Public Offering of $300 Million of Convertible Senior Notes due 2024

WALTHAM, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that it intends to offer, subject to market and other conditions, $300...
August 03, 2017 16:01 ET | Source: Radius Health Inc.

Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update

2Q’17 financial results reflect the first 4 weeks of TYMLOS sales in the U.S. Managed care contracts in place for coverage of over 130 million lives for TYMLOS™ (68% of all Commercial and 28% of...
July 21, 2017 16:05 ET | Source: Radius Health Inc.

Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos™ (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

WALTHAM, Mass., July 21, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...
July 18, 2017 07:00 ET | Source: Radius Health Inc.

Radius Health Announces New Employment Inducement Grant

WALTHAM, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to...
July 17, 2017 07:00 ET | Source: Radius Health Inc.

Radius Health Appoints Jesper Høiland as President and Chief Executive Officer To Lead The Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech Company

WALTHAM, Mass., July 17, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to...
July 13, 2017 07:39 ET | Source: Radius Health Inc.

Radius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan

Teijin granted a right of reference to Radius regulatory data and use of Radius Intellectual Property for development, manufacture and commercialization of abaloparatide-SC for Japan, the largest...
July 07, 2017 07:00 ET | Source: Radius Health Inc.

Radius Health to Announce Second Quarter 2017 Financial Results, Host Conference Call and Live Webcast on August 3, 2017

WALTHAM, Mass., July 07, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in...
June 04, 2017 09:00 ET | Source: Radius Health Inc.

Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)

-Elacestrant single agent Objective Response Rate (ORR) was 23% in heavily pre-treated patients with advanced ER+ breast cancer at the cut off date of April 28, 2017- -In the 400 mg patient...